Eli Lilly’s Omvoh (mirikizumab) beats J&J’s Stelara in head-to-head study

Posted by Michael Jannicelli | Oct 14, 2024 | Uncategorized | 0 |

Omvoh, another IL-23 inhibitor, is already FDA approved for UC and is now reporting good results for Crohn’s and performed better than Stelara.

Quote from the link:
“A greater number of patients that achieved histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075). In patients with active histologic disease at baseline and with at least one prior biologic failure, mirikizumab also showed greater histologic response at Week 52…

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.